US FDA rejects China lung cancer drug
The FDA rejected ivonescimab, a closely watched lung cancer drug from China. It had become a symbol of China's rise in drug development.
Why it matters
It affects Chinese drugmakers' hopes in the US market.
Background
The drug targets lung cancer.
The story so far
- US FDA rejects China lung cancer drug
- FDA rejects China's lung cancer drug ivonescimab
Sources
- The Straits Times ↗Nov 15, 7:57 PM ET
This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.